normative
FDA Should Demand Efficacy Evidence Eventually
Rather than blocking access, the FDA can reasonably approve a needed drug on surrogate-endpoint evidence, but it should require that studies of real clinical endpoints be ongoing at the time of approval; the problem is these confirmatory studies often never get done, leaving us using therapies that might not work.
normativepending
Speaker
Adam CifuEvidence Quote
“we never get that final data, and we are left with, you know, using therapies that might work but we are not sure they do.”
Created: 6/13/2026, 12:11:12 AM
Your notes
Loading notes...